Home > Pulmonology > Asthma rescue with budesonide-formoterol cuts short-term flare risk

Asthma rescue with budesonide-formoterol cuts short-term flare risk

Lancet Respiratory Medicine
Reuters Health - 09/10/2020 - Patients with mild asthma who aren't adhering to maintenance therapy have a lower short-term risk of severe exacerbations after a single day of increased use of as-needed budesonide-formoterol, according to a post-hoc analysis from the SYGMA 1 study. The more puffs of Symbicort a patient took, the lower the risk of a severe asthma flare over the next three weeks, Dr. Paul M. O'Byrne of McMaster University in Hamilton, Canada, and colleagues report in The Lancet Respiratory Medicine. Published in 2018, the phase 3 SYGMA 1 trial evaluated the benefit of Symbicort when used "as needed" by adults and adolescents with mild asthma who were not on maintenance treatment. It found that patients using Symbicort had a lower long-term risk of severe asthma exacerbations than patients using the short-acting beta2 agonist (SABA) terbutaline alone. Symbicort, made by AstraZeneca, is a combination of the inhaled corticosteroid budesonide and the...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on